A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers
Clinical trials show average weight loss of 15 to 17 percent of body weight over one year at this dose
Further investigation of the intestinal microbiome metabolism of orally supplemented l-carnitine in patients with IEMs is needed to answer the following questions raised by this study: (1) Does chronic oral l-carnitine supplementation increase the risk of atherosclerosis in individuals with organic acidemias
The results show that the administration of the complex significantly reduces the percentage of skin cells with a high melanin content by 16%, and that in skin irradiated with UVA/UVB, there is a decrease in the content of collagen, elastin and sulfate GAGs, and the complex reverses this reduction without changing MMP1 levels
May Help with Water Loss*
According to ClinicalTrials.gov, several bimolecular combinations alongside the dual GLP-1/GIP agonist tirzepatide are currently under investigation in phase 2 trials including eloralintide (NCT06603571), an amylin receptor agonist
